Philadelphia, November 10, 2025 — Verismo Therapeutics, a clinical-stage biotechnology company pioneering KIR-CAR T cell therapies, presented compelling preclinical data for SynKIR™-110 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The company’s oral presentation, selected among the top 150 abstracts out of over 1,300 submissions, showcased data demonstrating enhanced tumor regression, reduced cell exhaustion, and lower off-target toxicity compared to conventional CAR T therapies. These findings highlight a breakthrough approach to tackling the persistent challenges of treating solid tumors with engineered immune cell therapies.
Science Significance
The SynKIR™-110 therapy represents a significant scientific advancement in next-generation CAR T design, introducing a novel NK-cell-based split-signaling receptor system derived from killer immunoglobulin receptors (KIR). Preclinical studies showed that SynKIR™-110 sustains tumor-specific killing, reduces activation-induced exhaustion, and maintains functional persistence in vitro. In animal models, the therapy achieved deep and prolonged tumor regression in mesothelioma and other mesothelin-expressing cancers. This innovation could redefine the landscape of cellular immunotherapy, overcoming limitations of traditional 41BB-CD3ζ CAR T cells that struggle against solid tumor microenvironments.
Regulatory Significance
Regulatory momentum behind SynKIR™-110 is strong. The therapy has already earned Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for mesothelioma. Currently being evaluated in a Phase 1 clinical trial (NCT05568680), SynKIR™-110 is undergoing early human testing in advanced ovarian cancer, cholangiocarcinoma, and mesothelioma. These regulatory endorsements emphasize the potential clinical importance and unmet medical need of the platform, supporting faster development timelines and potential priority review pathways. For the cGxP community, this underscores a critical stage where preclinical promise transitions into GCP and GMP-regulated clinical manufacturing and testing environments, aligning with global standards of safety, efficacy, and quality assurance.
Business Significance
Advertisement
As a subsidiary of HLB Innovation, Verismo Therapeutics stands at the forefront of the Bio-Pharma sector, driving value through platform diversification and clinical pipeline expansion. Alongside SynKIR™-110, the company’s second asset, SynKIR™-310 (NCT06544265), is advancing in clinical studies, highlighting Verismo’s multi-asset strategy. The company’s proprietary KIR-CAR platform may offer licensing and partnership opportunities in the solid tumor immunotherapy market, an area with multibillion-dollar growth potential. Investor and partner interest are likely to strengthen as the therapy progresses through regulatory milestones, reflecting a robust commercial and translational trajectory.
Patients’ Significance
For patients with advanced mesothelioma, ovarian cancer, and cholangiocarcinoma, the potential of SynKIR™-110 offers new hope where treatment options remain limited. The data suggest a safer and more durable therapeutic response, with less off-target toxicity and reduced immune exhaustion — key factors for improving patient outcomes and quality of life. If clinical results confirm preclinical findings, SynKIR™-110 could mark a turning point in immunotherapy, broadening access to effective, personalized treatments for solid tumor patients who previously faced poor prognoses.
Policy Significance
The presentation at SITC 2025 underscores the alignment between scientific innovation and health policy priorities focused on accelerating advanced therapy medicinal products (ATMPs). As global regulators refine frameworks for cell and gene therapies, platforms like KIR-CAR exemplify responsible innovation under cGxP principles. Policymakers and industry stakeholders will be watching how KIR-CAR manufacturing, safety validation, and post-market surveillance evolve under FDA and EMA guidance. The regulatory recognition of SynKIR™-110 could influence policy incentives, encouraging similar innovations across the Bio-Pharma landscape.
Verismo Therapeutics’ SynKIR™-110 marks an exciting frontier in next-generation CAR T cell therapy, combining novel immunological design with rigorous preclinical validation. As the therapy advances through clinical stages under FDA Fast Track status, it has the potential to reshape the therapeutic paradigm for solid tumors. For the Bio-Pharma sector, this development exemplifies the intersection of science, regulation, and patient impact, driving forward the future of precision oncology under the guiding framework of cGxP excellence.
Source: Verismo Therapeutics press release
